NCT03770325View on ClinicalTrials.gov

A Mechanistic Randomized Controlled Trial on the Cardiovascular Effect of Berberine

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

November 1, 2020

Study Completion Date

November 1, 2020

Conditions
Cardiovascular Risk Factor
Interventions
DRUG

Berberine

Purified berberine (500 mg orally twice a day) in tablets for 12 weeks

DRUG

Placebo

Placebo tablets, prepared with the same appearance, for 12 weeks

Trial Locations (1)

Unknown

Li Ka Shing Faculty of Medicine, Hong Kong

All Listed Sponsors
collaborator

Food and Health Bureau, Hong Kong

OTHER_GOV

lead

The University of Hong Kong

OTHER

NCT03770325 - A Mechanistic Randomized Controlled Trial on the Cardiovascular Effect of Berberine | Biotech Hunter | Biotech Hunter